HC Wainwright Brokers Boost Earnings Estimates for Oculis

Oculis Holding AG (NASDAQ:OCS) – Equities researchers at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for Oculis in a research report issued on Thursday, March 13th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.43) for the quarter, up from their prior forecast of ($0.50). HC Wainwright has a “Buy” rating and a $29.00 price objective on the stock. The consensus estimate for Oculis’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.41) EPS and FY2025 earnings at ($1.63) EPS.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%.

Several other brokerages also recently commented on OCS. Chardan Capital reiterated a “buy” rating and set a $28.00 target price on shares of Oculis in a research note on Thursday, March 13th. Robert W. Baird lifted their target price on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a research note on Thursday, March 13th.

Oculis Stock Performance

Shares of NASDAQ OCS opened at $18.97 on Monday. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. Oculis has a 12 month low of $10.55 and a 12 month high of $23.08. The stock has a 50 day moving average of $20.96 and a 200-day moving average of $17.10. The company has a market capitalization of $828.27 million, a P/E ratio of -9.83 and a beta of 0.01.

Institutional Trading of Oculis

Several hedge funds have recently added to or reduced their stakes in OCS. abrdn plc lifted its holdings in Oculis by 23.0% during the 4th quarter. abrdn plc now owns 1,009,424 shares of the company’s stock worth $17,150,000 after purchasing an additional 188,871 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Oculis during the 4th quarter worth approximately $389,000. XTX Topco Ltd acquired a new stake in Oculis during the 4th quarter worth approximately $225,000. Bank of America Corp DE lifted its holdings in Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after purchasing an additional 10,667 shares during the last quarter. Finally, Bellevue Group AG acquired a new stake in Oculis during the 4th quarter worth approximately $170,000. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.